nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—BRAF—bone cancer	0.483	0.818	CbGaD
Dabrafenib—CYP3A4—bone cancer	0.107	0.182	CbGaD
Dabrafenib—SLCO1B3—Methotrexate—bone cancer	0.0466	0.176	CbGbCtD
Dabrafenib—ABCG2—Carboplatin—bone cancer	0.0389	0.147	CbGbCtD
Dabrafenib—ABCG2—Cisplatin—bone cancer	0.0332	0.125	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—bone cancer	0.0271	0.103	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—bone cancer	0.025	0.0946	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—bone cancer	0.0223	0.0841	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—bone cancer	0.0216	0.0814	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—bone cancer	0.0174	0.0659	CbGbCtD
Dabrafenib—ABCB1—Cisplatin—bone cancer	0.012	0.0452	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—bone cancer	0.00802	0.0303	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—bone cancer	0.00777	0.0294	CbGbCtD
Dabrafenib—CYP3A4—Doxorubicin—bone cancer	0.00481	0.0182	CbGbCtD
Dabrafenib—Urinary tract disorder—Cisplatin—bone cancer	0.000257	0.00332	CcSEcCtD
Dabrafenib—Connective tissue disorder—Cisplatin—bone cancer	0.000256	0.0033	CcSEcCtD
Dabrafenib—Urethral disorder—Cisplatin—bone cancer	0.000255	0.0033	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.000247	0.00318	CcSEcCtD
Dabrafenib—Eye disorder—Cisplatin—bone cancer	0.000244	0.00314	CcSEcCtD
Dabrafenib—Hyperkalaemia—Doxorubicin—bone cancer	0.000242	0.00313	CcSEcCtD
Dabrafenib—Rash maculo-papular—Epirubicin—bone cancer	0.000242	0.00312	CcSEcCtD
Dabrafenib—Neoplasm—Epirubicin—bone cancer	0.000241	0.00311	CcSEcCtD
Dabrafenib—Influenza like illness—Doxorubicin—bone cancer	0.000239	0.00309	CcSEcCtD
Dabrafenib—Immune system disorder—Cisplatin—bone cancer	0.000235	0.00304	CcSEcCtD
Dabrafenib—Mediastinal disorder—Cisplatin—bone cancer	0.000235	0.00303	CcSEcCtD
Dabrafenib—Arrhythmia—Cisplatin—bone cancer	0.000233	0.003	CcSEcCtD
Dabrafenib—Alopecia—Cisplatin—bone cancer	0.00023	0.00297	CcSEcCtD
Dabrafenib—Erythema—Cisplatin—bone cancer	0.000227	0.00293	CcSEcCtD
Dabrafenib—Malnutrition—Cisplatin—bone cancer	0.000227	0.00293	CcSEcCtD
Dabrafenib—Rash maculo-papular—Doxorubicin—bone cancer	0.000224	0.00289	CcSEcCtD
Dabrafenib—Renal failure acute—Methotrexate—bone cancer	0.000224	0.00289	CcSEcCtD
Dabrafenib—Neoplasm—Doxorubicin—bone cancer	0.000223	0.00288	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000222	0.00287	CcSEcCtD
Dabrafenib—Muscle spasms—Cisplatin—bone cancer	0.000218	0.00281	CcSEcCtD
Dabrafenib—Vision blurred—Cisplatin—bone cancer	0.000214	0.00276	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Epirubicin—bone cancer	0.000213	0.00275	CcSEcCtD
Dabrafenib—Anaemia—Cisplatin—bone cancer	0.00021	0.0027	CcSEcCtD
Dabrafenib—Renal failure acute—Epirubicin—bone cancer	0.00021	0.0027	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000206	0.00265	CcSEcCtD
Dabrafenib—Leukopenia—Cisplatin—bone cancer	0.000203	0.00262	CcSEcCtD
Dabrafenib—Dermatitis bullous—Epirubicin—bone cancer	0.000202	0.00261	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Doxorubicin—bone cancer	0.000197	0.00255	CcSEcCtD
Dabrafenib—Hyponatraemia—Epirubicin—bone cancer	0.000194	0.00251	CcSEcCtD
Dabrafenib—Renal failure acute—Doxorubicin—bone cancer	0.000194	0.0025	CcSEcCtD
Dabrafenib—Pain in extremity—Epirubicin—bone cancer	0.000193	0.0025	CcSEcCtD
Dabrafenib—Myalgia—Cisplatin—bone cancer	0.000193	0.00249	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000192	0.00247	CcSEcCtD
Dabrafenib—Dermatitis bullous—Doxorubicin—bone cancer	0.000187	0.00242	CcSEcCtD
Dabrafenib—Oedema—Cisplatin—bone cancer	0.000185	0.00239	CcSEcCtD
Dabrafenib—Infection—Cisplatin—bone cancer	0.000184	0.00237	CcSEcCtD
Dabrafenib—Nervous system disorder—Cisplatin—bone cancer	0.000182	0.00234	CcSEcCtD
Dabrafenib—Thrombocytopenia—Cisplatin—bone cancer	0.000181	0.00234	CcSEcCtD
Dabrafenib—Blood creatinine increased—Epirubicin—bone cancer	0.000181	0.00234	CcSEcCtD
Dabrafenib—Dehydration—Epirubicin—bone cancer	0.00018	0.00232	CcSEcCtD
Dabrafenib—Skin disorder—Cisplatin—bone cancer	0.00018	0.00232	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—bone cancer	0.00018	0.00232	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—bone cancer	0.000179	0.00231	CcSEcCtD
Dabrafenib—Hyperhidrosis—Cisplatin—bone cancer	0.000179	0.00231	CcSEcCtD
Dabrafenib—Dry skin—Epirubicin—bone cancer	0.000177	0.00229	CcSEcCtD
Dabrafenib—Abdominal pain upper—Epirubicin—bone cancer	0.000177	0.00228	CcSEcCtD
Dabrafenib—Hypokalaemia—Epirubicin—bone cancer	0.000176	0.00227	CcSEcCtD
Dabrafenib—Pancreatitis—Methotrexate—bone cancer	0.000175	0.00226	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000174	0.00225	CcSEcCtD
Dabrafenib—Hypotension—Cisplatin—bone cancer	0.000173	0.00223	CcSEcCtD
Dabrafenib—Nasopharyngitis—Epirubicin—bone cancer	0.000173	0.00223	CcSEcCtD
Dabrafenib—Abdominal discomfort—Methotrexate—bone cancer	0.000171	0.00221	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000171	0.0022	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000169	0.00218	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—bone cancer	0.000168	0.00216	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—bone cancer	0.000167	0.00216	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—bone cancer	0.000166	0.00215	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—bone cancer	0.000164	0.00212	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—bone cancer	0.000164	0.00211	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—bone cancer	0.000163	0.00211	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—bone cancer	0.000163	0.0021	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000161	0.00208	CcSEcCtD
Dabrafenib—Decreased appetite—Cisplatin—bone cancer	0.000161	0.00208	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—bone cancer	0.00016	0.00206	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Cisplatin—bone cancer	0.00016	0.00206	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—bone cancer	0.000159	0.00206	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—bone cancer	0.000159	0.00206	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000158	0.00204	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—bone cancer	0.000157	0.00202	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—bone cancer	0.000156	0.00202	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—bone cancer	0.000155	0.002	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—bone cancer	0.000152	0.00196	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—bone cancer	0.000152	0.00196	CcSEcCtD
Dabrafenib—Hyperglycaemia—Epirubicin—bone cancer	0.000151	0.00195	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—bone cancer	0.00015	0.00194	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—bone cancer	0.000149	0.00192	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—bone cancer	0.000149	0.00192	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—bone cancer	0.000147	0.00189	CcSEcCtD
Dabrafenib—Body temperature increased—Cisplatin—bone cancer	0.000146	0.00189	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—bone cancer	0.000145	0.00187	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—bone cancer	0.000145	0.00187	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—bone cancer	0.000145	0.00187	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—bone cancer	0.000144	0.00185	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—bone cancer	0.000143	0.00184	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—bone cancer	0.000142	0.00183	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—bone cancer	0.000141	0.00182	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—bone cancer	0.000141	0.00181	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—bone cancer	0.00014	0.00181	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—bone cancer	0.00014	0.0018	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—bone cancer	0.000138	0.00178	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—bone cancer	0.000138	0.00178	CcSEcCtD
Dabrafenib—Hypersensitivity—Cisplatin—bone cancer	0.000136	0.00176	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—bone cancer	0.000136	0.00175	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—bone cancer	0.000135	0.00174	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—bone cancer	0.000134	0.00173	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—bone cancer	0.000134	0.00173	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—bone cancer	0.000134	0.00173	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—bone cancer	0.000134	0.00172	CcSEcCtD
Dabrafenib—Asthenia—Cisplatin—bone cancer	0.000133	0.00171	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—bone cancer	0.000132	0.0017	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—bone cancer	0.000132	0.0017	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—bone cancer	0.000132	0.0017	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—bone cancer	0.000132	0.0017	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—bone cancer	0.000131	0.00169	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—bone cancer	0.00013	0.00168	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—bone cancer	0.00013	0.00167	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—bone cancer	0.000129	0.00167	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—bone cancer	0.000129	0.00166	CcSEcCtD
Dabrafenib—Chills—Methotrexate—bone cancer	0.000128	0.00166	CcSEcCtD
Dabrafenib—Diarrhoea—Cisplatin—bone cancer	0.000127	0.00163	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—bone cancer	0.000126	0.00163	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—bone cancer	0.000125	0.00162	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—bone cancer	0.000125	0.00161	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—bone cancer	0.000124	0.00161	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—bone cancer	0.000124	0.00161	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—bone cancer	0.000124	0.00161	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—bone cancer	0.000124	0.0016	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—bone cancer	0.000122	0.00158	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—bone cancer	0.000122	0.00157	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—bone cancer	0.000122	0.00157	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—bone cancer	0.000121	0.00157	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—bone cancer	0.000121	0.00157	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—bone cancer	0.000121	0.00156	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—bone cancer	0.000121	0.00156	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—bone cancer	0.00012	0.00155	CcSEcCtD
Dabrafenib—Chills—Epirubicin—bone cancer	0.00012	0.00155	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—bone cancer	0.00012	0.00154	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—bone cancer	0.000118	0.00153	CcSEcCtD
Dabrafenib—Vomiting—Cisplatin—bone cancer	0.000118	0.00152	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—bone cancer	0.000117	0.00151	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—bone cancer	0.000117	0.00151	CcSEcCtD
Dabrafenib—Rash—Cisplatin—bone cancer	0.000117	0.00151	CcSEcCtD
Dabrafenib—Dermatitis—Cisplatin—bone cancer	0.000117	0.0015	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—bone cancer	0.000116	0.0015	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—bone cancer	0.000116	0.0015	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—bone cancer	0.000116	0.00149	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—bone cancer	0.000115	0.00148	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—bone cancer	0.000113	0.00145	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—bone cancer	0.000112	0.00145	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—bone cancer	0.000112	0.00144	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—bone cancer	0.000112	0.00144	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—bone cancer	0.000112	0.00144	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—bone cancer	0.000111	0.00144	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—bone cancer	0.000111	0.00143	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—bone cancer	0.000111	0.00143	CcSEcCtD
Dabrafenib—Nausea—Cisplatin—bone cancer	0.00011	0.00142	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—bone cancer	0.00011	0.00142	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—bone cancer	0.000109	0.00141	CcSEcCtD
Dabrafenib—Cough—Methotrexate—bone cancer	0.000109	0.0014	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—bone cancer	0.000108	0.0014	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—bone cancer	0.000108	0.00139	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—bone cancer	0.000108	0.00139	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—bone cancer	0.000108	0.00139	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—bone cancer	0.000106	0.00137	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—bone cancer	0.000106	0.00137	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000105	0.00136	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—bone cancer	0.000104	0.00135	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—bone cancer	0.000104	0.00135	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—bone cancer	0.000104	0.00134	CcSEcCtD
Dabrafenib—Cough—Epirubicin—bone cancer	0.000102	0.00131	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—bone cancer	0.000102	0.00131	CcSEcCtD
Dabrafenib—Infection—Methotrexate—bone cancer	0.000101	0.0013	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—bone cancer	0.000101	0.0013	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—bone cancer	9.96e-05	0.00129	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—bone cancer	9.96e-05	0.00129	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—bone cancer	9.95e-05	0.00128	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—bone cancer	9.92e-05	0.00128	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—bone cancer	9.92e-05	0.00128	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—bone cancer	9.87e-05	0.00127	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	9.85e-05	0.00127	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—bone cancer	9.82e-05	0.00127	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—bone cancer	9.7e-05	0.00125	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—bone cancer	9.65e-05	0.00124	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—bone cancer	9.51e-05	0.00123	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—bone cancer	9.49e-05	0.00122	CcSEcCtD
Dabrafenib—Infection—Epirubicin—bone cancer	9.45e-05	0.00122	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—bone cancer	9.41e-05	0.00121	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—bone cancer	9.32e-05	0.0012	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—bone cancer	9.31e-05	0.0012	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—bone cancer	9.31e-05	0.0012	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—bone cancer	9.26e-05	0.00119	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—bone cancer	9.24e-05	0.00119	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—bone cancer	9.19e-05	0.00119	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—bone cancer	9.19e-05	0.00119	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—bone cancer	9.18e-05	0.00118	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—bone cancer	9.18e-05	0.00118	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	9.11e-05	0.00118	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—bone cancer	8.98e-05	0.00116	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—bone cancer	8.88e-05	0.00115	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—bone cancer	8.83e-05	0.00114	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—bone cancer	8.8e-05	0.00113	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—bone cancer	8.77e-05	0.00113	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—bone cancer	8.76e-05	0.00113	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—bone cancer	8.74e-05	0.00113	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—bone cancer	8.66e-05	0.00112	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—bone cancer	8.63e-05	0.00111	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—bone cancer	8.61e-05	0.00111	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—bone cancer	8.6e-05	0.00111	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—bone cancer	8.55e-05	0.0011	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—bone cancer	8.5e-05	0.0011	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—bone cancer	8.31e-05	0.00107	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—bone cancer	8.27e-05	0.00107	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—bone cancer	8.22e-05	0.00106	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—bone cancer	8.21e-05	0.00106	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—bone cancer	8.2e-05	0.00106	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—bone cancer	8.13e-05	0.00105	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—bone cancer	8.03e-05	0.00104	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—bone cancer	8.03e-05	0.00104	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—bone cancer	8.02e-05	0.00103	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—bone cancer	7.96e-05	0.00103	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—bone cancer	7.77e-05	0.001	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—bone cancer	7.65e-05	0.000987	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—bone cancer	7.6e-05	0.00098	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—bone cancer	7.58e-05	0.000978	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—bone cancer	7.52e-05	0.000971	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—bone cancer	7.52e-05	0.00097	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—bone cancer	7.52e-05	0.00097	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—bone cancer	7.49e-05	0.000966	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—bone cancer	7.29e-05	0.00094	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—bone cancer	7.19e-05	0.000928	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—bone cancer	7.19e-05	0.000927	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—bone cancer	7e-05	0.000904	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—bone cancer	6.95e-05	0.000897	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—bone cancer	6.95e-05	0.000897	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—bone cancer	6.95e-05	0.000897	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—bone cancer	6.82e-05	0.00088	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—bone cancer	6.73e-05	0.000868	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—bone cancer	6.72e-05	0.000867	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—bone cancer	6.51e-05	0.000839	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—bone cancer	6.48e-05	0.000836	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—bone cancer	6.46e-05	0.000833	CcSEcCtD
Dabrafenib—Rash—Methotrexate—bone cancer	6.41e-05	0.000826	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—bone cancer	6.4e-05	0.000826	CcSEcCtD
Dabrafenib—Headache—Methotrexate—bone cancer	6.36e-05	0.000821	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—bone cancer	6.31e-05	0.000814	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—bone cancer	6.29e-05	0.000811	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—bone cancer	6.22e-05	0.000803	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—bone cancer	6.05e-05	0.00078	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—bone cancer	6.03e-05	0.000779	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—bone cancer	6.02e-05	0.000777	CcSEcCtD
Dabrafenib—Rash—Epirubicin—bone cancer	5.99e-05	0.000773	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—bone cancer	5.99e-05	0.000773	CcSEcCtD
Dabrafenib—Headache—Epirubicin—bone cancer	5.96e-05	0.000768	CcSEcCtD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	5.83e-05	0.000857	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—KIT—bone cancer	5.83e-05	0.000857	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.83e-05	0.000857	CbGpPWpGaD
Dabrafenib—Dizziness—Doxorubicin—bone cancer	5.82e-05	0.00075	CcSEcCtD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—EGFR—bone cancer	5.81e-05	0.000854	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—TP53—bone cancer	5.78e-05	0.00085	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—KIT—bone cancer	5.78e-05	0.000849	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NDUFA12—bone cancer	5.77e-05	0.000849	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—KIT—bone cancer	5.74e-05	0.000844	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—KIT—bone cancer	5.73e-05	0.000842	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—BRAF—bone cancer	5.72e-05	0.00084	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—KIT—bone cancer	5.7e-05	0.000838	CbGpPWpGaD
Dabrafenib—Nausea—Epirubicin—bone cancer	5.65e-05	0.000729	CcSEcCtD
Dabrafenib—LIMK1—Axon guidance—EGFR—bone cancer	5.59e-05	0.000822	CbGpPWpGaD
Dabrafenib—Vomiting—Doxorubicin—bone cancer	5.59e-05	0.000722	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—bone cancer	5.55e-05	0.000716	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—bone cancer	5.54e-05	0.000715	CcSEcCtD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	5.54e-05	0.000814	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—CYP3A4—bone cancer	5.53e-05	0.000813	CbGpPWpGaD
Dabrafenib—Headache—Doxorubicin—bone cancer	5.51e-05	0.000711	CcSEcCtD
Dabrafenib—RAF1—Signaling by SCF-KIT—MDM2—bone cancer	5.51e-05	0.00081	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—BRAF—bone cancer	5.48e-05	0.000806	CbGpPWpGaD
Dabrafenib—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	5.46e-05	0.000802	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—JUN—bone cancer	5.45e-05	0.000801	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.35e-05	0.000786	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NDUFA12—bone cancer	5.35e-05	0.000786	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—JUN—bone cancer	5.27e-05	0.000775	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—MDM2—bone cancer	5.27e-05	0.000775	CbGpPWpGaD
Dabrafenib—Nausea—Doxorubicin—bone cancer	5.23e-05	0.000674	CcSEcCtD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—EGFR—bone cancer	5.21e-05	0.000765	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SPARC—bone cancer	5.2e-05	0.000764	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—MDM2—bone cancer	5.19e-05	0.000762	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—BRAF—bone cancer	5.18e-05	0.000761	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	5.17e-05	0.000759	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—MDM2—bone cancer	5.16e-05	0.000758	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—EGFR—bone cancer	5.15e-05	0.000757	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—JUN—bone cancer	5.05e-05	0.000742	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—BRAF—bone cancer	4.97e-05	0.000731	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—MDM2—bone cancer	4.95e-05	0.000728	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—MMP9—bone cancer	4.94e-05	0.000726	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—MDM2—bone cancer	4.93e-05	0.000725	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—MDM2—bone cancer	4.91e-05	0.000721	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—GRM4—bone cancer	4.89e-05	0.000718	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—RGS1—bone cancer	4.89e-05	0.000718	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—MDM2—bone cancer	4.88e-05	0.000717	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—bone cancer	4.88e-05	0.000717	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—EGFR—bone cancer	4.87e-05	0.000716	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—EGFR—bone cancer	4.87e-05	0.000716	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	4.87e-05	0.000716	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	4.86e-05	0.000714	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NT5C3A—bone cancer	4.78e-05	0.000703	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—EGFR—bone cancer	4.77e-05	0.0007	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—GNA11—bone cancer	4.76e-05	0.000699	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—GSTP1—bone cancer	4.73e-05	0.000696	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—EGFR—bone cancer	4.73e-05	0.000695	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—JUN—bone cancer	4.71e-05	0.000692	CbGpPWpGaD
Dabrafenib—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	4.67e-05	0.000686	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—MMP9—bone cancer	4.66e-05	0.000685	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—bone cancer	4.65e-05	0.000684	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—MDM2—bone cancer	4.61e-05	0.000678	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	4.59e-05	0.000675	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—MDM2—bone cancer	4.59e-05	0.000675	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—MDM2—bone cancer	4.59e-05	0.000675	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—MDM2—bone cancer	4.55e-05	0.000669	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—EGFR—bone cancer	4.54e-05	0.000667	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—MDM2—bone cancer	4.52e-05	0.000665	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—MDM2—bone cancer	4.51e-05	0.000663	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—MDM2—bone cancer	4.49e-05	0.00066	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—JUN—bone cancer	4.48e-05	0.000659	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.43e-05	0.000652	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NT5C3A—bone cancer	4.43e-05	0.000651	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.37e-05	0.000643	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—JUN—bone cancer	4.33e-05	0.000636	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TP53—bone cancer	4.33e-05	0.000636	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.32e-05	0.000635	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL3—bone cancer	4.31e-05	0.000634	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—EGFR—bone cancer	4.29e-05	0.00063	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—JUN—bone cancer	4.29e-05	0.00063	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—GRM1—bone cancer	4.24e-05	0.000623	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RGS1—bone cancer	4.17e-05	0.000613	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GRM4—bone cancer	4.17e-05	0.000613	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.17e-05	0.000612	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—MDM2—bone cancer	4.17e-05	0.000612	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—JUN—bone cancer	4.16e-05	0.000612	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	4.14e-05	0.000609	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	4.07e-05	0.000598	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	4.02e-05	0.000591	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—bone cancer	4e-05	0.000588	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	3.99e-05	0.000587	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—EGFR—bone cancer	3.99e-05	0.000587	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ATF1—bone cancer	3.98e-05	0.000585	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KIT—bone cancer	3.97e-05	0.000584	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—bone cancer	3.97e-05	0.000584	CbGpPWpGaD
Dabrafenib—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.92e-05	0.000576	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ENO2—bone cancer	3.84e-05	0.000564	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MET—bone cancer	3.82e-05	0.000561	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KIT—bone cancer	3.82e-05	0.000561	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—BRAF—bone cancer	3.81e-05	0.00056	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—JUN—bone cancer	3.77e-05	0.000554	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—EGFR—bone cancer	3.77e-05	0.000553	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.76e-05	0.000552	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—BRAF—bone cancer	3.73e-05	0.000549	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.71e-05	0.000545	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.7e-05	0.000543	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GRM1—bone cancer	3.62e-05	0.000532	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	3.6e-05	0.000529	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—EGFR—bone cancer	3.6e-05	0.000529	CbGpPWpGaD
Dabrafenib—BRAF—Disease—DHFR—bone cancer	3.56e-05	0.000523	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—EGFR—bone cancer	3.55e-05	0.000521	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—EGFR—bone cancer	3.53e-05	0.000518	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—EGFR—bone cancer	3.39e-05	0.000498	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—EGFR—bone cancer	3.37e-05	0.000495	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—EGFR—bone cancer	3.37e-05	0.000495	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—EGFR—bone cancer	3.35e-05	0.000493	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—EGFR—bone cancer	3.34e-05	0.00049	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—bone cancer	3.33e-05	0.00049	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NDUFA12—bone cancer	3.32e-05	0.000488	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—EGFR—bone cancer	3.27e-05	0.000481	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—MDM2—bone cancer	3.19e-05	0.000469	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.19e-05	0.000469	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP2—bone cancer	3.19e-05	0.000468	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—EGFR—bone cancer	3.14e-05	0.000461	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—EGFR—bone cancer	3.14e-05	0.000461	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	3.14e-05	0.000461	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—MDM2—bone cancer	3.13e-05	0.00046	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ENO2—bone cancer	3.12e-05	0.000458	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—EGFR—bone cancer	3.11e-05	0.000457	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—EGFR—bone cancer	3.09e-05	0.000454	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—EGFR—bone cancer	3.08e-05	0.000453	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—EGFR—bone cancer	3.07e-05	0.000451	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—MDM2—bone cancer	3e-05	0.000442	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—SMO—bone cancer	2.99e-05	0.000439	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—EGFR—bone cancer	2.97e-05	0.000436	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.95e-05	0.000434	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—DHFR—bone cancer	2.89e-05	0.000425	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NDUFA12—bone cancer	2.89e-05	0.000425	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GRM4—bone cancer	2.89e-05	0.000424	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RGS1—bone cancer	2.89e-05	0.000424	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PLAU—bone cancer	2.83e-05	0.000416	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	2.78e-05	0.000409	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.75e-05	0.000404	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NT5C3A—bone cancer	2.75e-05	0.000404	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—bone cancer	2.75e-05	0.000404	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—GNA11—bone cancer	2.73e-05	0.000401	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CDK4—bone cancer	2.73e-05	0.000401	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MET—bone cancer	2.73e-05	0.000401	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GNA11—bone cancer	2.7e-05	0.000397	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.69e-05	0.000395	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ENO2—bone cancer	2.66e-05	0.00039	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—JUN—bone cancer	2.61e-05	0.000384	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFBR2—bone cancer	2.58e-05	0.000379	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SMO—bone cancer	2.55e-05	0.000375	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.54e-05	0.000373	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.51e-05	0.000368	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GRM1—bone cancer	2.5e-05	0.000368	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.48e-05	0.000364	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL3—bone cancer	2.48e-05	0.000364	CbGpPWpGaD
Dabrafenib—RAF1—Disease—DHFR—bone cancer	2.46e-05	0.000362	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CYP3A4—bone cancer	2.45e-05	0.00036	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.44e-05	0.000358	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NT5C3A—bone cancer	2.39e-05	0.000352	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP9—bone cancer	2.39e-05	0.000352	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GNA11—bone cancer	2.33e-05	0.000343	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ATF1—bone cancer	2.32e-05	0.000341	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP2—bone cancer	2.27e-05	0.000334	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KIT—bone cancer	2.27e-05	0.000333	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL3—bone cancer	2.26e-05	0.000332	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KIT—bone cancer	2.18e-05	0.00032	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ATF1—bone cancer	2.17e-05	0.000318	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—EGFR—bone cancer	2.14e-05	0.000314	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL3—bone cancer	2.11e-05	0.000311	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSTP1—bone cancer	2.1e-05	0.000308	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ENO2—bone cancer	2.1e-05	0.000308	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EGFR—bone cancer	2.05e-05	0.000302	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.04e-05	0.0003	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.96e-05	0.000289	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—DHFR—bone cancer	1.94e-05	0.000286	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ENO2—bone cancer	1.94e-05	0.000285	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—EGFR—bone cancer	1.94e-05	0.000284	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GNA11—bone cancer	1.82e-05	0.000267	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFBR2—bone cancer	1.81e-05	0.000266	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—DHFR—bone cancer	1.8e-05	0.000265	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFBR2—bone cancer	1.79e-05	0.000262	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MDM2—bone cancer	1.78e-05	0.000262	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NDUFA12—bone cancer	1.78e-05	0.000262	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.77e-05	0.00026	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SMO—bone cancer	1.76e-05	0.000259	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KIT—bone cancer	1.76e-05	0.000259	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—MDM2—bone cancer	1.71e-05	0.000252	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—bone cancer	1.71e-05	0.000251	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1R—bone cancer	1.7e-05	0.00025	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GNA11—bone cancer	1.68e-05	0.000247	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP3A4—bone cancer	1.65e-05	0.000242	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.64e-05	0.000241	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GNA11—bone cancer	1.61e-05	0.000237	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—JUN—bone cancer	1.55e-05	0.000228	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP3A4—bone cancer	1.53e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ATF1—bone cancer	1.5e-05	0.00022	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NT5C3A—bone cancer	1.48e-05	0.000217	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL3—bone cancer	1.46e-05	0.000215	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTP1—bone cancer	1.41e-05	0.000207	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.39e-05	0.000205	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MDM2—bone cancer	1.39e-05	0.000204	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—bone cancer	1.38e-05	0.000203	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—bone cancer	1.34e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KIT—bone cancer	1.32e-05	0.000194	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTP1—bone cancer	1.3e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFBR2—bone cancer	1.25e-05	0.000184	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KIT—bone cancer	1.23e-05	0.000181	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—bone cancer	1.22e-05	0.000179	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KIT—bone cancer	1.22e-05	0.000179	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO2—bone cancer	1.2e-05	0.000177	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1R—bone cancer	1.18e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—bone cancer	1.17e-05	0.000172	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.17e-05	0.000172	CbGpPWpGaD
Dabrafenib—RAF1—Disease—BRAF—bone cancer	1.15e-05	0.000168	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—bone cancer	1.14e-05	0.000167	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—DHFR—bone cancer	1.12e-05	0.000164	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—bone cancer	1.09e-05	0.00016	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO2—bone cancer	1.05e-05	0.000154	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNA11—bone cancer	1.04e-05	0.000153	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MDM2—bone cancer	1.04e-05	0.000153	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—DHFR—bone cancer	9.73e-06	0.000143	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MDM2—bone cancer	9.71e-06	0.000143	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MDM2—bone cancer	9.6e-06	0.000141	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—bone cancer	9.48e-06	0.000139	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP3A4—bone cancer	9.47e-06	0.000139	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.42e-06	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—bone cancer	9.25e-06	0.000136	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNA11—bone cancer	9.1e-06	0.000134	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JUN—bone cancer	9.03e-06	0.000133	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—bone cancer	8.53e-06	0.000125	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUN—bone cancer	8.44e-06	0.000124	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP3A4—bone cancer	8.25e-06	0.000121	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—bone cancer	8.21e-06	0.000121	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—bone cancer	8.1e-06	0.000119	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—bone cancer	8.02e-06	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—bone cancer	7.77e-06	0.000114	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—bone cancer	7.3e-06	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—bone cancer	7.1e-06	0.000104	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—bone cancer	7.05e-06	0.000104	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—bone cancer	6.76e-06	9.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MDM2—bone cancer	6.72e-06	9.88e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—bone cancer	6.64e-06	9.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—bone cancer	6.56e-06	9.64e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO2—bone cancer	6.46e-06	9.5e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DHFR—bone cancer	6e-06	8.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUN—bone cancer	5.84e-06	8.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—bone cancer	5.68e-06	8.35e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNA11—bone cancer	5.6e-06	8.24e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—bone cancer	5.57e-06	8.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—bone cancer	4.59e-06	6.75e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—bone cancer	4.35e-06	6.39e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—bone cancer	4.19e-06	6.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—bone cancer	3.86e-06	5.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—bone cancer	3.65e-06	5.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—bone cancer	2.25e-06	3.31e-05	CbGpPWpGaD
